Taiho Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company and a core subsidiary of Otsuka Holdings. The company focuses on the research, development, manufacturing, and marketing of prescription medicines, with a leading position in oncology, and also supplies selected specialty and over-the-counter healthcare products.
Taiho’s R&D emphasizes small-molecule chemistry and targeted therapies. Its oncology portfolio includes fluoropyrimidine-based agents such as S-1/TS-1 (marketed as Teysuno in some regions), the nucleoside antitumor combination trifluridine/tipiracil (Lonsurf), and the FGFR inhibitor futibatinib (Lytgobi). The company conducts clinical development across Asia, the Americas, and Europe, and uses a mix of in-house capabilities and external partnerships for development and commercialization. Taiho develops and manufactures active pharmaceutical ingredients and finished dosage forms for its products and pipeline, operating to international quality standards. Its global footprint includes subsidiaries such as Taiho Oncology, Inc. in the United States.
Official website: taiho.co.jp
